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Abstract
Background: The presence of risk factors have a high risk of developing breast cancer. Our study aimed to find an
association between sociodemographic factors and the risk of estrogen receptor (ER)-positive, progesterone receptor (PR)positive breast cancer among women. Methods: A cross-sectional study was conducted on 200 women with breast cancer.
Association between sociodemographic factors and hormone receptor subtypes of breast cancer was found using the Chisquare test. Multiple logistic regression analysis was used to know the strong predictors of hormone receptor subtypes.
Results: The mean age was 50.08 (10.67) years. Comorbidities had a statistically significant association with ER-positive
subtype (p = 0.007). Body mass index had a statistically significant association with PR-positive subtype (p = 0.042).
Comorbidities was found to be the strong independent predictor for ER-positive (OR 2.28; 95% CI: 1.28–4.05, p = 0.01)
and PR-positive subtypes (OR 1.78; 95% CI: 1.01–3.13, p = 0.03). Conclusion: We conclude that in our study, body
mass index was associated with PR-positive subtype, and comorbidities were associated with ER-positive subtype of
breast cancer among the women. Comorbidities remained to be a strong independent predictor of ER-positive and PRpositive subtypes of breast cancer.
Keywords: body mass index, breast cancer, comorbidities, estrogen receptor, progesterone receptor

factors in patients may help them to use for the
remission. Our study aimed to know the association
between sociodemographic factors and hormone receptor
subtypes, namely, estrogen receptor (ER)-positive and
progesterone receptor (PR)-positive, of breast cancer.

Introduction
As per the World Health Organization, breast cancer
accounts for 14% of all cancers among Indian women
and killing 627,000 globally. In India, the incidence
rates are high in the early thirties and reach its pinnacle
between 50 and 64 years.1 The risk of breast cancer
grows exponentially, with the presence of risk factors
such as age, age at menopause, menopausal status, age
at first delivery, family history, breastfeeding history,
number and spacing of births, use of oral contraceptives,
diet, and physical activity. Many research studies reported
a significant association between sociodemographic risk
factors such as physical activity,2 family history,3
breastfeeding,4 and body mass index (BMI),5,6
comorbidities.7–9 Awareness about these risk factors and
education on managing modifiable risk factors can help
prevent breast cancer to some extent.

Methods
We carried out a descriptive cross-sectional study on
200 breast cancer patients, attending the Department of
Medical Oncology and having confirmed diagnosis and
hormone receptor subtypes of breast cancer. The study
duration was six months (01/08/2019 to 31/01/2020).
Institutional Ethical Committee approved our study
(VIPT/IEC/68/2019). We performed the study
according to the guidelines outline in the Declaration of
Helsinki, 1964. Informed consent was obtained from
patients who were willing to participate.

Modifiable risk factors such as BMI and physical activity
decrease the worsening of cancer and improve the
remission response to the treatment. These factors do
not bother the patients much. Comorbidities, however,
cannot be modified but can be managed. Indeed, BMI
and physical activity will influence the severity of the
comorbidities. Awareness about these sociodemographic

Patients with the following criteria were included in the
study: confirmed diagnosis, first time and referral
patients, with comorbidities, and complete diagnostic
data on receptor subtypes. Patients with the following
criteria were excluded: with HIV as comorbidity,
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critically ill patients, recurrent breast cancer, and
referral to surgery.
Simple random sampling technique was used to select
the breast cancer patients. The estimated sample size
was 197 (margin of error 5%, the confidence level 95%,
population size 400, and response distribution 50%).
Breast cancer cells with ERs are called ER-positive
(ER+) and vice versa. Breast cancer cells with PRs are
PR-positive (PR+) and vice versa. Menopausal status was
defined by criteria based on Breast Cancer Surveillance
Consortium.10 Postmenopausal status was defined as age
≥55 years or report of natural menopause or removal of
both ovaries or current use of hormone therapy or 365
days since last menstrual period. Premenopausal status
was defined as no stopping of menstrual periods or
ongoing use of birth control hormones or <180 days since
last menstrual period. BMI was categorized based on the
Asian population indices.11 Patients with BMI <18.5
kg/m2 were categorized as underweight, with BMI
between 18.5 and 22.9 kg/m2 as normal, with BMI
between 23.0 and 24.9 kg/m2 as overweight, and with
BMI ≥25 kg/m2 as obese. Physical activity was defined as
performing activities like running or jogging intensely for
at least three days a week with a minimum of 20 minutes
per session for intense work-up or a minimum of 30
minutes per session for moderate work-up like for
elderly.12
The data collection was divided into three parts. The
first part deals with collecting sociodemographic details
like age, marital status, comorbidities, menopausal
status, physical activity, family history, number of live
births, age at first delivery, and breastfeeding history.
The second part consists of collecting clinical details
like type of cancer, tumor grade, tumor size, lymph
node status, type of treatment, and receptor status of
breast cancer. The third part deals with tabulation and
analysis of the data.
Frequencies and percentages were calculated for
qualitative data. Shapiro-Wilk test was applied on the
quantitative data. Based on the normality assumptions,
data were represented as mean and standard deviation or
median and interquartile range, whichever is
appropriate. Chi-square test was performed to find out
any significant association between independent
variables and receptor status. Multivariate logistic
regression analysis was performed to predict the
independent risk factor for the hormone receptor
subtype of breast cancer. Odds ratio and 95%
confidence intervals were used to show the results of the
analysis. The level of significance was considered at p <
0.05. Jeffrey’s Amazing Statistics Program (JASP,
version 0.12.1) software was used for the statistical
analysis of the data.
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Results
Table 1 presents an overview of the sociodemographic
characteristics of the patients. The mean (SD) age of
breast cancer patients in our study was 50.38 (10.67)
years. The age group 41–55 was high (43.5%) in
frequency. The frequency of patients without
comorbidities (55.5%), no family history of breast cancer
(90.5%), no history of breastfeeding (85.5%), no physical
activity (66.0%) was high. The table also shows the high
frequency of number of live births ≤ 3 (83.5%) and obese
patients (45.0%).
Table 2 outlines the clinical characteristics of breast
cancer patients in our study. Our study’s most observed
pathologic type of breast cancer was the invasive ductal
type (89.0%). The frequency of patients with tumor size
between 2 and 5 cm (60.5%), stage II (67.5%), and grade
II tumors (66.0%) were high. Patients with lymph node
status, N2 (31.5%), and receiving three modalities of
treatment (42.0%) were found to be high in frequency.
ER-positive breast cancer patients account for 54%. PRpositive breast cancer patients account for 46%.
Table 1. Sociodemographic characteristics of the patients
Name of the characteristics
Age (in years)
25–40
41–55
55–70
70–85
Comorbidities
Yes
No
Physical Activity
Yes
No
Family History
Yes
No
Menopausal Status
Premenopausal
Postmenopausal
Breastfeeding history
Yes
No
No. of live births
≤3
≥3
Body Mass Index
Underweight
Normal
Overweight
Obese
Age at first pregnancy
<30
≥30

Frequency (%)
50 (25.0)
87 (43.5)
59 (29.5)
4 (2.0)
89 (44.5)
111 (55.5)
68 (34.0)
132 (66.0)
19 (9.5)
181 (90.5)
175 (87.5)
25 (12.5)
29 (14.5)
171 (85.5)
167 (83.5)
33 (16.5)
15 (7.5)
66 (33.0)
29 (14.5)
90 (45.0)
176 (88.0)
24 (12.0)
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Table 3 outlines the statistically significant association
between comorbidities and estrogen receptor subtype.
Table 4 depicts a significant association between BMI
and progesterone receptor subtype.
Table 2. Clinical characteristics of the patients
Name of the characteristic

Frequency (%)

Pathologic type
Invasive ductal

7 (3.5)

Medullary

8 (4.0)

Papillary

7 (3.5)

Tumor size
12 (6.0)

T2 (2–5 cm)

121 (60.5)

T3 (>5 cm)

67 (33.5)

Tumor staging
Stage I

17 (8.5)

Stage II

135 (67.5)

Stage III

48 (24.0)

Tumor grade
Grade I

13 (6.5)

Grade II

132 (66.0)

Grade III

55 (27.5)

Lymph node status
N0 (0)

45 (22.5)

N1 (1–3)

56 (28.0)

N2 (4–9)

63 (31.5)

N3 (≥10)

36 (18.0)

Estrogen receptor subtype
Positive

108 (54.0)

Negative

92 (46.0)

Progesterone receptor subtype
Positive

92 (46.0)

Negative

108 (54.0)

Type of treatment
CT + RT + ET

84 (42.0)

CT + RT

78 (39.0)

CT

32 (16.0)

Others

6 (3.0)

CT: Chemotherapy, RT: Radiotherapy, ET: Endocrine
Therapy, Others: RT (3) and ET (3).

Table 5 shows that the odds ratio of ER-positive
patients with comorbidities are 2.28 times (OR = 2.28;
95% CI: 1.28–4.05; p = 0.01) than that of patients with
Makara J Health Res.

Table 3. Association of sociodemographic variables with the
estrogen receptor subtype

178 (89.0)

Invasive lobular

T1 (<2 cm)

no comorbidities. The odds ratio of PR-positive patients
with comorbidities are 1.78 times (OR = 1.78; 95% CI:
1.01–3.13; p = 0.03) than that of patients with no
comorbidities. We observed comorbidities as an
independent risk factor for hormone receptor-positive
subtypes of breast cancer.

Sociodemographic
variables

Estrogen receptor
subtype
Positive Negative

Total

p

Age in years
25–40

24

26

50

41–55

48

39

87

55–70

34

25

59

70–85

2

2

4

No

75

57

132

Yes

33

35

68

No

94

87

181

Yes

14

5

19

Underweight

10

5

15

Normal

35

31

66

Overweight

19

10

29

Obese

44

46

90

Premenopause

97

78

175

Postmenopause

11

14

25

No

93

78

171

Yes

15

14

29

Yes

58

31

89

No

50

61

111

≤3

92

75

167

≥3

16

17

33

≤25 years

94

76

170

25–35 years

14

16

30

0.774

Physical activity
0.265

Family history
0.070

Body mass index
0.322

Menopausal status
0.283

Breastfeeding history
0.790

Comorbidities
0.007*

No. of live births
0.617

Age at first pregnancy
0.382

*p < 0.05
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Table 4. Association of sociodemographic variables with the progesterone receptor subtype
Sociodemographic
variables
Age in years
25–40
41–55
55–70
70–85
Physical activity
No
Yes
Family history
No
Yes
Body mass index
Underweight
Normal
Overweight
Obese
Menopausal status
Premenopause
Postmenopause
Breastfeeding history
No
Yes
Comorbidities
Yes
No
No. of live births
≤3
≥3
Age at first pregnancy
≤25 years
25–35
*p < 0.05

Progesterone receptor subtype
Positive
Negative

Total

p

20
39
31
2

30
48
28
2

50
87
59
4

63
29

69
39

132
68

0.494

81
11

100
8

181
19

0.274

9
24
19
40

6
42
10
50

15
66
29
90

83
9

92
16

175
25

0.283

78
14

93
15

171
29

0.790

48
44

41
67

89
111

0.061

81
11

86
22

167
33

0.159

77
15

93
15

170
30

0.633

0.611

0.042*

Table 5. Multiple logistic regression analysis of sociodemographic variables and hormone receptor subtypes of breast cancer
Name of the variables

Estrogen receptor subtype

Progesterone receptor subtype

Age

OR (95% CI)
1.08 (0.65–2.19)

Family history

2.32 (0.89–7.49)

0.05

1.39 (0.65–4.14)

0.69

Comorbidities

2.28 (1.28–4.05)

0.01*

1.78 (1.01–3.13)

0.03*

Body mass index

0.59 (0.54–1.82)

0.55

1.52 (0.92–3.18)

0.05

Physical activity

1.19 (0.77–2.51)

0.16

1.29 (0.60–2.21)

0.69

Menopausal status

1.85 (0.68–3.68)

0.19

1.68 (0.67–3.82)

0.19

Breastfeeding history

1.31 (0.50–2.44)

0.47

0.98 (0.40–1.97)

0.47

No. of live births

1.28 (0.61–2.75)

0.30

1.68 (0.85–4.12)

0.07

Age at first pregnancy

0.74 (0.34–1.50)

0.24

1.27 (0.55–2.26)

0.38

*p

p
0.32

OR (95% CI)
0.89 (0.37–1.25)

p
0.14

< 0.05; OR= Odds Ratio; CI =Confidence Interval.
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Discussion
The age group 41–55 years was found to be of high risk
for breast cancer. Studies from India reported varying
age groups ranging from 40 to 60 years. 13–15 Age at
different points in women’s lives, such as menarche,
first pregnancy, menopause, increases the risk of
breast cancer. Family history score (FHS) is a new
methodology that considers the expected numbers of
the family cohort, cumulative person-years in the family
cohort, and corresponding national annual, age-specific
breast cancer incidence rates. A combination of FHS
and age at diagnosis of breast cancers in relatives
would be a good predictor of breast cancer risk.3
Invasive ductal carcinoma was the most common form
of breast cancer in our study. Two studies reported
similar results. 16,17 The Majority of tumors belonged to
T2 (2–5 cm) category, stage II, and grade II in our
study. Prior study18 reported similar findings to tumor
category and grade. Other studies reported stage IV17
and stage III16 as predominant type of tumors. Lymph
node involvement was reported by previous study19;
however, the study did not specify the number of
lymph nodes involved. ER-positive patients (54%) and
PR-negative patients were high in our study. Few
studies reported similar results for ER-positive
patients.16,17,19
Hormone receptor subtypes influence the outcome of
breast cancer patients. For example, preceding study19
reported significantly improved overall survival in ERpositive and PR-positive patients than in ER-negative
and PR-negative patients. Another study20 also
reported a decreased incidence of local and distant
recurrence in ER-positive and PR-positive patients
than in ER-negative and PR-negative patients.
Breastfeeding for a minimum duration of 12 months
shown to decrease a 4% reduction of breast cancer. 21 A
case-control study also reported a decreased risk in
premenopausal women with a long breastfeeding
duration.22 Breastfeeding was associated with hormone
receptor subtype of breast cancer. Previous study4
reported a significant inverse association between ERnegative breast cancer and breastfeeding. Even a
shorter duration of breastfeeding (<6 months) may
decrease ER-negative breast cancer.
Unlike age, family history, we can modify physical
activity and body mass index to decrease the risk of
breast cancer. Vigorous physical activity and being
overweight or obese, between 18–30 years, decrease
the risk of breast cancer. 2 Hypothesized mechanisms
include physical activity that decreases body fat,
estrogen, and androgen levels. It modifies acquired
immune response and promotes the elimination of
cancer cells.23,24 Being overweight or obese throughout
Makara J Health Res.

adulthood increases the risk of postmenopausal breast
cancer.2
We observed a significant association between BMI and
the PR subtype. High BMI is a risk factor for breast
cancer. However, the risk of breast cancer varies based on
menopausal status. BMI increase, along with parity and
menopausal status, constitutes a risk factor for ERpositive breast cancer. Previous study5 observed that
parity and an increase in BMI affected the risk of ER
subtypes of breast cancer. Nulliparous women and an
increase in BMI (5.0–9.9 kg/m2 or ≥10 kg/m2) decreased
the risks of ER-positive breast cancer. However, a change
in BMI was not related to the risk of ER-positive breast
cancer among parous women.
A meta-analysis on the effect of BMI on menopausal
status concluded that BMI has no significant effect on
the incidence of breast cancer during the
premenopausal period. 22 Another study 6 also reported
a relation between higher BMI at the time of diagnosis
of breast cancer and a higher risk of recurrence and
death, specifically in hormone receptor-positive
disease. Although a significant association was
reported with hormone receptor-negative breast
cancer, hormone receptor-positive breast cancer
showed a stronger association with BMI.25
Hypothesized mechanisms that explain the association
between high BMI and recurrence/metastasis include
insulin, a steroid hormone, adipokine, and
inflammatory pathways. They may promote breast
cancer cell proliferation and tumor growth. 6,26
In our study, comorbidities were significantly associated
with ER subtype breast cancer. Multiple logistic
regression analysis results also suggested comorbidity as
a strong independent risk factor for ER-positive and PRpositive breast cancers. Comorbidities affect the survival
outcomes of patients with breast cancer and hormone
receptor subtypes. For example, previous study7 observed
that premenopausal women with diabetes had more often
PR-negative breast cancer. Another study8 also reported a
similar association between premenopausal diabetic
women and PR-negative breast cancer. However, other
study27 reported a significant association between
premenopausal women and ER-negative breast cancer.
Earlier study9 reported increased odds of triple-negative
(ER-/PR-/HER-) breast cancer was higher among diabetic
women or who had used a diabetes medication for a long
duration before cancer diagnosis compared with
nondiabetic women.
There are many reasons of how comorbidities decrease
the overall disease prognosis: reduces the likelihood of
receiving guideline-recommended treatment,28–31 elevates
the risk of chemotherapy-induced adverse effects,32,33
and lower quality of life.34 Hypertension and obesity
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increase the risk of heart failure with trastuzumab, and
worse functional health.35,36
Our study observed an association between BMI and
comorbidities with PR and ER subtypes. Comorbidities
were a strong independent risk factor for both ERpositive and PR-positive breast cancers. There are a few
limitations to our study. As the sample size was small,
we cannot generalize our findings for the women with
ER or PR subtype of breast cancer. Due to the small
sample size, we could not find which comorbidity was
associated with the hormone receptor subtypes.

7.

Conclusion

10.

8.

9.

We conclude in our study that BMI and comorbidities
are associated with PR and ER subtypes, respectively.
Comorbidity was found to be a strong independent risk
factor for both ER-positive and PR-positive breast
cancer patients in our study.
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